Halozyme
HALO Nasdaq· Biotechnology
Last close · Oct 23, 2026
$125.63
KIRA · Stoqly’s AI analyst, in plain words
- Halozyme had $1.4B of revenue in fiscal 2025, up 37.6% on the year before. Over five years, revenue changed +39.2% a year on average.
- Its operating margin was 33.6%, down 20.7 pts: of every 100 in sales, about 34 is left after running the business.
- Halozyme made $317M of net profit in fiscal 2025.
- Free cash flow was $645M in fiscal 2025, 46.2% of revenue.
- Halozyme returned $342M to shareholders in fiscal 2025, 53% of free cash flow. The diluted share count fell 4.3%.
- Halozyme owes $2.0B more than it holds in cash, about 4.2 years of operating profit.
Market cap
$15.2B
P/E
36.6x
Revenue
$1.4B
Net income
$317M
Free cash flow
$645M
Operating margin
33.6%
Halozyme in 30 seconds · fiscal 2025
Are sales growing?
+37.6%
Yes. Sales grew 37.6% last year.
Does it make a profit?
22.7%
Yes. It keeps 22.7% of every sale as profit.
Does profit turn into cash?
46.2%
Yes. 46.2% of sales ends up as free cash.
Is debt under control?
4.2x
Heavy. Repaying its debt would take 4.2 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
36.6x
One share costs 36.6 times its yearly profit per share. Typical for its sector: 27.9x.
What Halozyme does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- HALOZYME THERAPEUTICS, INC.
- CIK
- 0001159036
Halozyme · HALO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $443M | $660M | $829M | $1.0B | $1.4B |
| Revenue growth | 65.7% | 48.9% | 25.6% | 22.4% | 37.6% |
| Gross margin | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% |
| Operating margin | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Net income | $403M | $202M | $282M | $444M | $317M |
| Net margin | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| Diluted EPS | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Cash | |||||
| Cash from operations | $299M | $240M | $389M | $479M | $652M |
| Capital expenditure | $1.5M | $4.8M | $15.3M | $10.7M | $7.0M |
| Free cash flow | $298M | $235M | $373M | $468M | $645M |
| FCF margin | 67.2% | 35.7% | 45.0% | 46.1% | 46.2% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $350M | $200M | $402M | $250M | $342M |
| Share count change | 3.8% | −4.2% | −4.6% | −3.6% | −4.3% |
| Debt and strength | |||||
| Cash and short-term investments | $741M | $363M | $336M | $596M | $143M |
| Debt incl. finance leases | $787M | $1.5B | $1.5B | $1.5B | $2.1B |
| Shareholders' equity | $197M | $170M | $83.8M | $364M | $48.8M |
| Net debt / EBITDA | 0.2x | 4.2x | 3.3x | 1.6x | 4.2x |
| Current ratio | 7.9x | 5.7x | 6.6x | 7.8x | 4.7x |
| Interest coverage | 36.7x | 15.8x | 18.0x | 30.5x | 25.9x |
| Returns and quality | |||||
| Return on capital | — | 27.9% | 21.3% | 34.9% | 19.2% |
| Return on equity | 231.4% | 110.2% | 222.1% | 198.4% | 153.6% |
| Piotroski F-score | 5 | 4 | 6 | 9 | 5 |
| Altman Z'' | 6.5 | 3.5 | 3.9 | 5.6 | 3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$48.4M
5 insiders
Of sales under plans
95%
$46.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Halozyme · HALO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Halozyme HALO | $15.2B | 37.6% | 33.6% | 46.2% | 19.2% | 36.6x | 5 |
| Moderna MRNA | $79.1B | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 |
| Harmony Biosciences HRMY | $2.1B | 21.5% | 24.0% | 40.1% | 48.9% | 11.7x | 5 |
| Exelixis EXEL | $16.9B | 7.0% | 37.6% | 37.8% | 64.9% | 20.5x | 6 |
| Arrowhead Pharmaceuticals ARWR | $8.3B | 23,258.2% | 11.9% | 18.9% | — | — | 5 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $125.63 a share, the company is worth $15.2B: 36.6 times its earnings of the last four quarters.
Halozyme grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 2 of 2.
Source: SEC EDGAR XBRL filings (CIK 0001159036). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.